The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass
Open accessAbstract
Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 GLP-1 or Exendin-4 (Ex-4) activates beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal beta-cell regeneration (nSTZ model), the capacity of in vivo treatments with GLP-1 or Ex-4 to promote beta-cell regeneration. To this end, nSTZ rats from the Wistar strain (W) were submitted to GLP-1 or Ex-4 administration from postnatal day 2 to day 6 only, and their beta-cell masses were tested on day 7 (a) and (b). In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, total beta-cell masses per pancreas were both significantly increased (***P < .001) as compared with values in untreated nSTZ rats, representing, respectively, 51% and 71% of the control Wistar beta-cell mass, while nSTZ beta-cell mass represented only 21% of the control Wistar value. Beta-cell BrdU labeling index (c) in the untreated nSTZ rats was found to be significantly increased (P < .001) as compared with Wistar group. In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, it was similarly increased. A representative figure is given with double immunostaining for BrdU and insulin in 7-day-old nSTZ rats (magnification ×1000). To estimate activation of neogenesis (d) and (e), the number of single beta-cells incorporated into the duct epithelium and the number of beta-cell clusters budding from ducts were quantified. The number of isolated beta-cell within pancreatic tissue of nSTZ rats represented 185% of Wistar value and the number of beta-cell buds in pancreatic tissue in nSTZ rats represented 106% of Wistar value. These two parameters were strongly increased in nSTZ/GLP-1 and nSTZ/Ex-4 rats as compared to untreated nSTZ rats (***P < .001). A representative figure is given with indirect immunoperoxydase staining for insulin in 7 day-old nSTZ/GLP-1 rats (magnification ×1000). Adapted from Tourrel et al. [83].](https://figures.cochat.ai/paper-figures/c544b531910d4ce2ba066166796bc3e4/activation-of-the-glp-1-receptor-signalling-pathway-a-relevant-strategy-to-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This not only prevents the phosphorylation of JNK but also promotes the phosphorylation of STAT3, aiding the shift of macrophages to an anti-inflammatory M2 phenotype.327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Specifically, activation of GLP-1R leads to an increase in cAMP levels, which in turn activates PKA, a widely regulating enzyme of cellular functions, capable of phosphorylating a variety of target proteins, thereby initiating the PKA/CREB signaling pathway.326,327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969
A Family of cAMP-Binding Proteins That Directly Activate Rap1
Kawasaki, H., Springett, G. M., Mochizuki, N., Toki, S., Nakaya, M., Matsuda, M., Housman, D. E., & Graybiel, A. M. (1998) · Science · doi:10.1126/science.282.5397.2275 · Cited by 1,362
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
IPF1, a homeodomain-containing transactivator of the insulin gene.
Ohlsson, H., Karlsson, K., & Edlund, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06109.x · Cited by 888
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion
Wang, Y., Okamoto, M., Schmitz, F., Hofmann, K., & Südhof, T. C. (1997) · Nature · doi:10.1038/41580 · Cited by 684
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Research works printed but not linked: 6
- 10.1210/en.143.6.2303 · doi:10.1210/en.143.6.2303
- 10.1210/en.142.3.1218 · doi:10.1210/en.142.3.1218
- 2000, Journal of Clinical Endocrinology and Metabolism, 85, 3892
- 10.1002/(SICI)1097-4652(199912)181:3<470::AID-JCP11>3.0.CO;2-P · DOI
- 2002, American Journal of Physiology, 283, E745
- 2008, The New England Journal of Medicine, 358, 1970
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“AD rodent models chronically treated with the GLP-1 analog Val(8)glucagonlike peptide-1 caused modulation of neurotransmitter release, synaptic transmission (LTP) formation, and restoration of synaptic plasticity, as well as preventing impairment in the learning of new spatial tasks (328–330).”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Jakubowicz, D., & Froy, O. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.07.008 · Cited by 246
Metadata
- Authors
- Portha, B., Tourrel-Cuzin, C., & Movassat, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), Equipe 1, Université Paris-Diderot et CNRS EAC 4413, Bâtiment BUFFON, 5ème étage, pièce 552A, 4, Rue Lagroua Weill Hallé, Case 7126, 75205 Paris Cedex 13, France
- Corresponding author
- Portha, Bernard
- ORCID
- Movassat, Jamileh
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3118608
- OpenAlex
- W2091979481
- Cited by
- 85
- References
- 110
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 11
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, beta-cell mass, beta-cell neogenesis, beta-cell proliferation, beta-cell survival, type 2 diabetes, islet mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Cell Transformation, Neoplastic, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Middle Aged, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Receptors, Glucagon, Insulin-Secreting Cells, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass. https://app.cochat.ai/papers/10.1155/2011/376509
- The paper
- Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011). Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass. Experimental Diabetes Research. https://doi.org/10.1155/2011/376509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.